

Supplemental Notice of Allowability	Application No.	Applicant(s)
	10/621,807	DOWEYKO ET AL.
	Examiner KATHLEEN BRAGDON	Art Unit 1656

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 3/27/2008.
2. The allowed claim(s) is/are 1,5-7,9,10 and 29.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date _____
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

SUPPLEMENTAL EXAMINER'S AMENDMENT

1. An examiner's amendment to the record, supplemental to the examiner's amendment mailed March 27, 2008, appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Melissa Handler on June, 19, 2008.

The application has been amended as follows:

Claim 1, in (c),

delete “, thereby identifying the chemical entity as a modulator”
and replace with “, thereby identifying the chemical entity that binds GR Site II”

Claim 5, in (c),

delete “, thereby identifying the chemical entity as a modulator”
and replace with “, thereby identifying the chemical entity as a ligand of GR Site II”

Claim 6, in (c),

after “, thereby identifying the test molecule as a modulator”
and insert “of GR”

Claim 29, in (c),

delete “, thereby identifying the test molecule as a modulator”
and replace with “, thereby identifying the test molecule as a ligand of GR Site II”

The Examiner's amendment mailed on March 27, 2008 includes a Reasons for Allowance that is maintained herein.

Any inquiry concerning this communication should be directed to KATHLEEN BRAGDON at telephone number (571)272-0931.

/Kathleen Kerr Bragdon/

Kathleen Kerr Bragdon
SPE
Art Unit 1656